Latest News about BMY
Recent news which mentions BMY
Investor Optimism Improves Following Earnings, Economic Reports; Dow Jumps Over 350 Points
February 02, 2024
From Benzinga
Amazon, Apple And 3 Stocks To Watch Heading Into Friday
February 02, 2024
From Benzinga
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
January 30, 2024
From Benzinga
Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts?
January 30, 2024
From Benzinga
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
January 29, 2024
From Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
From Benzinga
3 Healthcare Stocks at 52-Week Lows: Buy or Bye?
January 26, 2024
From InvestorPlace
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer'
January 24, 2024
From Benzinga
7 Beaten-Down Value Stocks Poised for an Epic Turnaround
January 23, 2024
From InvestorPlace
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
January 23, 2024
From Benzinga
Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup
January 23, 2024
From Benzinga
From Benzinga
Bristol Myers' Lead Cancer Immunotherapy Shows Progression Free Survival Versus Chemo In Certain Type Of Colorectal Cancer
January 22, 2024
From Benzinga
Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes
January 19, 2024
From Benzinga
Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering?
January 18, 2024
From Benzinga
Behind the Scenes of Bristol-Myers Squibb's Latest Options Trends
January 16, 2024
Tickers
BMY
From Benzinga
Financial Relief For Medicare Patients: Part D Overhaul Caps Out-of-Pocket Drug Cost Limits
January 16, 2024
From Benzinga
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
January 12, 2024
From Benzinga
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
January 08, 2024
From Benzinga
3 Magnificent High-Yield Dividend Stocks to Buy in 2024
January 06, 2024
From Motley Fool
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
From Benzinga
Looking Into Bristol-Myers Squibb's Recent Short Interest
January 05, 2024
Tickers
BMY
From Benzinga
3 Dividend Stocks for Strong Returns in 2024 and Beyond
January 04, 2024
From InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
January 04, 2024
From Benzinga
7 Stocks Primed for a Spectacular Comeback in 2024
January 03, 2024
From InvestorPlace
This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns
January 03, 2024
From Benzinga
3 Strong Dividend Stocks to Buy Early On in 2024
January 03, 2024
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.